[HTML][HTML] Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial
…, S Koppelstätter, D Haschka, V Petzer… - European …, 2021 - Eur Respiratory Soc
Background After the 2002/2003 severe acute respiratory syndrome outbreak, 30% of
survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary …
survivors exhibited persisting structural pulmonary abnormalities. The long-term pulmonary …
[HTML][HTML] COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
…, N Khanna, GA Méndez, V Petzer… - Journal of hematology & …, 2021 - Springer
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
[HTML][HTML] Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients' performance: a prospective …
…, K Kurz, S Koppelstätter, D Haschka, V Petzer… - Respiratory …, 2020 - Springer
Background Severe coronavirus disease 2019 (COVID-19) is frequently associated with
hyperinflammation and hyperferritinemia. The latter is related to increased mortality in COVID-19…
hyperinflammation and hyperferritinemia. The latter is related to increased mortality in COVID-19…
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
…, I Espigado, M Cernan, V Petzer… - Blood, The Journal …, 2022 - ashpublications.org
Limited data are available on breakthrough COVID-19 in patients with hematologic
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
M Asshoff, V Petzer, MR Warr… - Blood, The Journal …, 2017 - ashpublications.org
Patients with myelofibrosis (MF) often develop anemia and frequently become dependent
on red blood cell transfusions. Results from a phase 2 study for the treatment of MF with the …
on red blood cell transfusions. Results from a phase 2 study for the treatment of MF with the …
[HTML][HTML] Iron in the tumor microenvironment—connecting the dots
C Pfeifhofer-Obermair, P Tymoszuk, V Petzer… - Frontiers in …, 2018 - frontiersin.org
Iron metabolism and tumor biology are intimately linked. Iron facilitates the production of
oxygen radicals, which may either result in iron-induced cell death, ferroptosis, or contribute to …
oxygen radicals, which may either result in iron-induced cell death, ferroptosis, or contribute to …
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report
…, JÁ Hernández‐Rivas, V Petzer… - American journal of …, 2022 - Wiley Online Library
To the Editor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has
caused high mortality in patients with hematological malignancies (HM). 1 The newly …
caused high mortality in patients with hematological malignancies (HM). 1 The newly …
[HTML][HTML] Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the …
…, DS Hersby, F Magyari, J Van Praet, V Petzer… - Journal of Hematology & …, 2023 - Springer
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe
Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (…
Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (…
[HTML][HTML] Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
…, J Labrador, C Buquicchio, S El-Ashwah, V Petzer… - …, 2023 - thelancet.com
Background Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in
immunocompetent patients with COVID-19, but data on efficacy in patients with haematological …
immunocompetent patients with COVID-19, but data on efficacy in patients with haematological …
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
…, MC Tisi, G Plantefeve, V Petzer… - Blood …, 2023 - ashpublications.org
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a
prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a …
prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a …